Related Experiment Videos
Effect of interferon therapy in a patient with chronic active hepatitis type C associated with interstitial pneumonia
T Kurihara1, K Abe, H Ishiguro
1Department of Gastroenterology (Institute of Geriatrics), Aoyama Hospital, Tokyo Women's Medical College, Japan.
Abstract:
Interferon (IFN) is widely used to treat patients with chronic hepatitis types B and C but has been found to occasionally aggravate rheumatoid arthritis (RA) or cause interstitial pneumonia. We administered 6 MIU/d IFN-beta by intravenous injection for 6 weeks to a 55-year-old man with chronic active hepatitis type C associated with RA and interstitial pneumonia. Transaminase levels rapidly returned to normal after treatment and hepatitis C virus-RNA (nested RT-PCR method) was negative on completion of treatment. No significant adverse reactions or aggravation of RA or interstitial pneumonia occurred. These findings suggest that use of IFN-beta in the treatment of patients with chronic hepatitis type C associated with RA and/or interstitial pneumonia presents no problem if appropriate precautions are taken.
Insights
Interferon beta effectively treated chronic hepatitis C in a patient with rheumatoid arthritis and interstitial pneumonia. Careful monitoring showed no worsening of these conditions during treatment.
Area of Science:
- Hepatology
- Rheumatology
- Pulmonology
Background:
- Interferon (IFN) is a standard treatment for chronic hepatitis B and C.
- IFN therapy can sometimes exacerbate rheumatoid arthritis (RA) or cause interstitial pneumonia.
- The safety of IFN-beta in patients with co-existing hepatitis C, RA, and interstitial pneumonia requires careful consideration.
Observation:
- A 55-year-old male patient with chronic active hepatitis C, RA, and interstitial pneumonia received 6 MIU/day of IFN-beta intravenously for 6 weeks.
- The patient's transaminase levels normalized rapidly during treatment.
- Hepatitis C virus-RNA became undetectable using nested RT-PCR post-treatment.
Findings:
- IFN-beta treatment led to a complete virologic response in the patient.
- No significant adverse reactions were observed.
- Existing RA and interstitial pneumonia did not show aggravation during the IFN-beta therapy.
Implications:
- IFN-beta can be a safe and effective treatment option for chronic hepatitis C in patients with RA and interstitial pneumonia.
- Appropriate precautions and monitoring are crucial for managing potential adverse events.
- This case suggests that IFN-beta therapy is feasible in complex patient profiles with careful clinical management.